CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

doi:10.1002/bcp.70370

Article

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

British journal of clinical pharmacology - 1 Feb 2026

Dello Russo Cinzia, Frater Iain, Kuruvilla Rebecca, Lip Stefanie, O'Neill Hannah, Burke Kerry, Chaplin Vicky, Doney Alexander S F, Elyas Salim, Greaves Nicholas, Harding Sophie, Hargroves David, Hayward Judith, Hughes Dyfrig A, Hughes Tom A T, Kondapally Sree, Mok Patrick, Peace Aaron, Rafi Imran, Ray Simon, Stinton Vicky, Venetucci Luigi, Pirmohamed Munir

Abstract excerpt

Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective. CYP2C19 is encoded by a polymorphic gene; variants in the CYP2C19 gene, which vary in...

Topics

Join the communities discussing this publication.

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

Abstract excerpt

Topics

Discuss the evidence

Related research